Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension From RCC Phase II (11515)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients are classified into two groups as below at transition date from Study 11515 to this study.~Population I: Patients who are willing to continue the study drug, for whom the investigator consider continuation of the study drug is appropriate, and who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515.~Population II: Patients who have been monitored only for survival status at the end of Study 11515.~Population 1~1. Patients who are willing to continue the study drug,~2. Patients for whom the investigator consider continuation of the study drug is appropriate~3. Patients who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515.~4. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Population 2~1. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Exclusion Criteria:~1. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results~2. Any condition that could jeopardize the safety of the patient or that affect his/her compliance in the study~3. Pregnant or breast-feeding patients. Both men and women enrolled in this trial must use adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Nexavar, BAY43-9006) (Type: EXPERIMENTAL): Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).